





公告日期	2026/3/3
異動類別	藥品變更
異動原因	年度招標
異動描述	Lenalidomide 10mg/cap (Leavdo)瑞伏駭10毫克因年度招標異動，改以Lenalidomide 10mg/cap (Revlimid)瑞復美膠囊10毫克替代。 ● 舊品用罄，啟用新品。

異動內容		
	舊藥品	新藥品
料號	524522	524829
學名	Lenalidomide	
商品名	Leavdo	Revlimid
中文名	瑞伏駭10毫克 (7/片)	瑞復美膠囊10毫克 (7/片)
主成份及含量	10mg/cap	
製造廠名稱	台灣東洋藥品工業股份有限公司中壢廠 (台灣東洋藥品工業股份有限公司中壢廠)	Celgene International Sarl (賽基)
產地	臺灣	瑞士
健保代碼	AC59668100	BC25216100
外觀/圖檔	  	  
用法	口服	

成人劑量	PO. Follicular lymphoma, previously treated: Oral: 20 mg qd for 21 days of a 28-day treatment cycle Multiple myeloma, mantle cell lymphoma : 25 mg QD. Multiple myeloma, maintenance (following ASCT) : 10 mg QD, after 3 cycles may increase to 15 mg QD if tolerated. Marginal zone lymphoma:20 mg qd for 21 days of a 28-day treatment cycle Myelodysplastic syndrome: 10 mg QD.	Follicular lymphoma, Marginal zone lymphoma: 20 mg QD for D1~21 in a 28-day cycle (in combination with rituximab) for up to 12 cycles Mantle cell lymphoma: 25 mg QD for D1~21 in a 28-day cycle Multiple myeloma: <u>In combination with dexamethasone:</u> 25 mg QD for D1~21 in a 28-day cycle <u>In combination with bortezomib and dexamethasone:</u> 25 mg QD for D1~14 in a 21-day cycle as initial therapy for 8 cycles; then 25 mg QD for D1~21 in a 28-day cycle (in combination with dexamethasone) as maintenance therapy <u>In combination with melphalan and prednisolone:</u> 10 mg QD for D1~21 in a 28-day cycle as initial therapy for 9 cycles; then 10 mg QD for D1~21 in a 28-day cycle as maintenance therapy Multiple myeloma, maintenance therapy following autologous stem cell transplant (ASCT): 10 mg QD. If tolerated, may increase dose to 15 mg once daily after 3 cycles (84 days). Myelodysplastic syndrome: 10 mg QD for D1~21 in a 28-day cycle.
副作用		